Vendor Intelligence Report: Orbitrex Peptides

Executive summary

Orbitrex’s strongest signal is testing, but it is not evenly transferable across the catalog. Across 26 Finnrick lab tests, Orbitrex records 21 pass / 2 fail and an overall pass rate of 81%. GHK-Cu and Retatrutide are the best-supported choices in the current record, while Tirzepatide is the conditional buy; the full report shows how those ratings shift under stricter grading.

The business is more traceable than an alias-only peptide shop. Texas formation records tie Orbitrex to a named principal, and a second Orbitrex entity appears later in the file. The buyer-facing address resolves to a commercial mailbox, while fulfillment clues point toward South Dakota without identifying the facility. The site’s Veteran Owned claim remains unverified in the open record.

The most acute risk is buying the wrong Orbitrex. The legitimate .com-to-.is storefront sits beside a documented lookalike-domain scam pattern involving small spelling changes, suffixes, and non-card payment demands. Because checkout was captured as ACH and cryptocurrency rather than standard credit card, domain verification is a financial control, not a cosmetic step.

Reputation signals need filtering. A Trustpilot profile cited in May at 112+ reviews and 4.0/5 was gone by June for guideline violations, and Orbitrex is promoted through a visible code/referral ecosystem that includes a launch consultant publicly tying himself to the owner. Lab data remains the anchor; coupon posts and review badges should not be.

Inside the full report:

• Appendix A Finnrick lab data with per-product pass/fail rates, trajectories, and methodology-divergence charts for all 3 tested products
• Corporate-record mapping of the primary Texas company, the later Orbitrex entity, and the named principal
• Address and fulfillment analysis covering the commercial mailbox, South Dakota shipping clues, and policy-page disclosures
• Domain and payment-stack review of the .com-to-.is redirect, Cloudflare, NMI-style gateways, ACH, crypto, and affiliate tracking
• Copycat-domain evidence from BBB Scam Tracker, Reddit, PeptideCritic, and Finnrick directory warnings
• Affiliate and reputation-signal review covering Trustpilot removal, X referral codes, coupon pages, and launch-consultant posts

Risk assessment

• Copycat / brand-confusion risk — high: Multiple lookalike domains are documented or warned against, including orbitrexspeptide.com, orbitrexpeptidesco.com, orbixtrexpeptideco.com, and orbitrextpeptidelab.com; vendor-side authentication signals remain insufficient for the scale of confusion.
• Trustpilot review-signal failure — high: The Trustpilot profile previously cited as 112+ reviews at 4.0/5 was removed for guideline violations; the exact violation is undisclosed, so prior review claims should not be relied upon.
• Payment-recourse risk — medium: Checkout was documented as ACH via Link Money and cryptocurrency, not standard credit card; buyers lose normal chargeback protection, especially dangerous when imposters are active.
• Affiliate-promotion risk — medium: Code/ref-link promotion is visible across X and coupon pages, including launch-consultant promotion, with limited clear post-level disclosure.
• Unverified veteran-owned marketing risk — medium: The site markets “Veteran Owned,” but investigators found no open-source verification of military service for the named principal, Calvin P. Newton.
• Tirzepatide quality-consistency concern — medium: Product-specific: Tirzepatide is Orbitrex’s weakest tested product in the supplied Finnrick record at 78.42% with 4 tests, 3 pass, and 1 fail; GHK-Cu and Retatrutide test stronger.